Clinical Trials Logo

Pruritus clinical trials

View clinical trials related to Pruritus.

Filter by:

NCT ID: NCT04393675 Recruiting - Uremic Pruritus Clinical Trials

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients

Start date: May 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A Randomized, Double Blind, Placebo-Controlled study to assess the Safety, Local Tolerance, and Pharmacokinetics of LT5001 drug product in Hemodialysis Patients with Uremic Pruritus

NCT ID: NCT04365244 Completed - Pruritus Clinical Trials

Pruritus and Melanoma and Cutaneous Carcinomas Treated With Immunotherapy

PRURICHECKPOIN
Start date: August 19, 2019
Phase:
Study type: Observational

Immune checkpoint inhibitors (ICIs) are commonly used in the therapeutic arsenal of metastatic melanoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma, thanks to their inhibiting effects on cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and anti-programmed death-1 (anti-PD1) respectively. These treatments can induce numerous cutaneous and non-cutaneous adverse effects that are mainly due to their immunological action. Their most frequent adverse effects are dysthyroidism, autoimmune hepatitis, colitis and skin disorders. Among those, pruritus is frequently reported as a side effect of these treatments. Its incidence has been estimated between 11% and 47%. Pruritus can deeply affect the patient's quality of life and may lead to treatment discontinuation. Until now, ICI-related pruritus has been poorly studied and it is not understood. In the literature, data on the presence and characteristics of pruritus in patients treated by ICIs were provided, without analyzing the causes of this pruritus. Indeed, it is not known if the occurrence of pruritus is related to direct or indirect effects of ICIs. Some authors reported a correlation between the occurrence of cutaneous adverse events under ICIs and the survival. The principal aim of our study was to analyze the putative causes of pruritus occurring in patients treated with ICIs for melanomas and cutaneous carcinomas. The other objectives were to assess the association between the occurrence of pruritus and survival, and between the other adverse events and pruritus.

NCT ID: NCT04337073 Completed - Pruritus Clinical Trials

The Effect of Propofol on Dexamethasone-induced Perineal Pruritus

Start date: September 1, 2020
Phase: Early Phase 1
Study type: Interventional

patients may appear serious perineal itching, after injection of dexamethasone sodium phosphate injection its incidence is about 25% ~ 100%, and the incidence of the discomfort in females was much higher than that of the maleTo investigate the effect of propofol pretreatment on perineal pruritus induced by dexamethasone sodium phosphate injection and explore the possible machanisms.

NCT ID: NCT04326738 Completed - Pruritus Clinical Trials

The Effect of Midazolam on Dexamethasone-induced Perineal Pruritus

Start date: January 16, 2020
Phase: Early Phase 1
Study type: Interventional

Dexamethasone is commonly used in clinical practice.However, intravenous dexamethasone sodium phosphate may cause perineal discomfort.With the popularization of comfortable medical technology, patients have higher and higher requirements for comfortable medical treatment.Perineal pruritus caused by intravenous dexamethasone sodium phosphate may cause adverse physiological and psychological effects on patients and increase the incidence of unpleasant experiences during anesthesia.Therefore, it is very important to find a practical and effective method of inhibition.Midazolam is a water-soluble benzodiazepine commonly used in clinical practice, which has been proved to effectively inhibit the itching caused , while its effect on the itching caused by dexamethasone has not been reported.By observing the effect of pre-injection midazolam on the perineal itching caused by dexamethasone sodium phosphate, this experiment intends to preliminarily explore its possible mechanism .

NCT ID: NCT04325802 Withdrawn - Atopic Dermatitis Clinical Trials

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

Start date: December 31, 2022
Phase: Phase 2
Study type: Interventional

Purpose: To study the etiology and the epigenetic pathways leading to and regulating chronic itch. Similarly, to examine the mechanisms underlying skin changes, including epigenetic alterations while also testing the efficacy of opioid antagonists in atopic dermatitis. In this study, the investigators aim to examine chronic sensory disorder mechanisms related to chronic itch.

NCT ID: NCT04317209 Recruiting - Pruritus Clinical Trials

A Study of SHR0410 in Hemodialysis Patients With Pruritus

Start date: May 17, 2020
Phase: Phase 1
Study type: Interventional

The aim of this study is to evaluate the safety, tolerability and pharmacokinetics of SHR0410 in hemodialysis patients with moderate to severe pruritus

NCT ID: NCT04316533 Completed - Psoriasis Clinical Trials

Work Stress and Impact of Pruritus on Quality of Life

PRUERI
Start date: March 9, 2020
Phase:
Study type: Observational

Work stress and pruritus: imbalance of effort balance reward in patients with psoriasis.

NCT ID: NCT04289038 Completed - Pruritus Clinical Trials

The Efficacy of VR and AR on Pruritus

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The research will be conducted randomly in order to determine the effect of VR and AR on pruritus symptom.

NCT ID: NCT04256759 Recruiting - Pruritus Clinical Trials

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.

NCT ID: NCT04160598 Recruiting - Clinical trials for Magnesium Infusion in Post-spinal Opioid Pruritis

Effect of Intravenous Magnesium on Post-spinal Fentanyl Induced Pruritus Incidence

Start date: September 2, 2020
Phase: N/A
Study type: Interventional

Introduction: Adding opioids to local anesthetic solutions leads to enhanced anesthesia and provide postoperative analgesia. Intrathecaly injected opioids have some side effects, though. One of them is pruritus. Objective: We designed a randomized, double-blinded, placebo-controlled study to evaluate prophylactic impact of continuous IV Magnesium 10mg/kg over 30 minutes on intrathecal fentanyl-induced pruritus start at the end of the operation. Methods: ASA I-II Patient's candidate for orthopedic operations under spinal anesthesia (10-15mg hyperbaric bupivacaine and 25 µg fentanyl intrathecal) and will be divided randomly into two groups: Control group (Placebo group): bolus 100 ml nacl 0.9% at end of surgery Study group (Mg ++ group): (continuous IV Magnesium 10mg/kg in 100 ml Nacl0.9% over 30 minutes at end of surgery). Study outcome: 1. Hemodynamics: Systolic blood pressure, Mean arterial blood pressure, pulse rate, O2 saturation will be recorded in 5 min,10 min,30 min,60 min and every one hour till 6 hours after the operation. 2. Pruritus Patients were asked about existence (present=1,no=0), severity (mild=1, modret=2, sever =3) and site of pruritus (Face(trigeminal) =1, neuroaxial(dermatome)=2), 1,2,4, and 6 hours after operation. Incidence of pruritus total group incidence %. 3. The incidence of PONV.